Research Paper

CircNF1-419 improves the gut microbiome structure and function in AD-like mice

Chen Diling^{1,*}, Qi Longkai^{1,*}, Guo Yinrui¹, Liu Yadi^{1,2}, Tang Xiaocui¹, Zhu Xiangxiang^{1,4}, Zeng Miao^{1,5}, Li Ran⁶, Shuai Ou¹, Wang Dongdong¹, Xie Yizhen¹, Yuan Xujiang², Burton B. Yang¹, Wu Qingping¹

¹State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangdong Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, China
²Guangdong Pharmaceutical University, Guangzhou 510006, China
³Guangxi University of Chinese Medicine, Nanning 530023, China
⁴Academy of Life Sciences, Jinan University, Guangdong Province, Guangzhou 510000, China

⁵Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China

⁶Department of Physiology, Shantou University Medical College, Shantou 515063, China

*Equal contibution

 Correspondence to: Yuan Xujiang, Wu Qingping; email: xjyuan.xj@163.com, wuqp203@163.com

 Keywords: circular RNAs, microbiome-gut-brain axis, dietary interventions, gut microbiome, therapeutic markers

 Received: August 12, 2019
 Accepted: December 5, 2019

 Published: January 6, 2020

Copyright: Diling et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Our pre-experiments found that the brain circRNA sequence profiles and gut microbiota in AD-like mice were changed, as circNF1-419 could enhance autophagy to ameliorate senile dementia in AD-like mice, so we conclude that there might some connections between circRNA and gut microbiome. Therefore, we use the over-expressed *circNF1-419* adeno-associated virus (AAV) animal system with the aim of identifying possible connections. Our results showed that over-expression of circ*NF1-419* in brain not only influenced the cholinergic system of brain, but also changed the gut microbiota composition as the *Candidatus Arthromitus*, *Lachnospiraceae FCS020 group*, *Lachnospiraceae UCG-006*, and [Eubacterium] *xylanophilum group*, and the intestinal homeostasis and physiology, and even the gut microbiota trajectory in new born mice. These findings demonstrate a link between circRNA and gut microbiome, enlarge the 'microbiome- transcriptome' linkage library and provide more information on gut-brain axis.

INTRODUCTION

The microbiota-gut-brain axis integrates neural, hormonal and immunological signaling between the gut and brain, and has a profound effect on mammalian growth and health throughout life [1, 2]. However, systematic linkage of the two distant organs and the physiological and pathological impacts of the microbiota-gut-brain axis on growth and health remain largely unclear. Extensive research is required to validate existing routes of bidirectional communication, to identify new connections, and to illuminate the relevant molecular mechanisms. In previous studies, we found that alterations of gut microbiota and transcriptomes of the small intestine and brain are accompanied by changes in the concentrations of $A\beta_{1-42}$ in the hippocampal CA1 region [3]. Furthermore, probiotics of fructo-oligosaccharides from natural herbs could modulate these interactions between gut ecology and brain physiology [3], indicating that the gut microbiota and brain interact with each other. However, additional evidence is needed, particularly clinical

sample support, and the mechanism remains poorly understood and requires further investigation.

Research increasingly suggests that diet and lifestyle are important factors for human health. A vast array of paradigms have confirmed that many common diseases are more or less related to obesity, such as sleep apnea [4], infertility [5], diabetes [6], hypertension [7], coronary heart disease [8], liver disease [9, 10], osteoporosis [11], cancers [12, 13], and even Alzheimer's disease (AD) [14]. Weight management is therefore particularly important for keeping healthy. In traditional concepts, body weight (or more accurately, body fat) is considered to be regulated by the central nervous system (CNS). However, recent studies have confirmed that symbiotic microorganisms also play an important role regarding fluctuations in energy status [15–18], and fecal microbiota transplantation could influence acute feeding behavior and long-term energy homeostasis [19, 20]. Within this symbiotic interaction, a clear understanding of who drives decisions about when, how much, what and why is lacking.

Circular RNA (circRNA) is a type of single-stranded RNA which, unlike the better known linear RNA, forms a covalently closed continuous loop, i.e., in circular RNA the 3' and 5' ends normally present in an RNA molecule have been joined together [21]. This feature confers numerous properties to circRNAs, many of which have only recently been identified. As circRNAs do not have 5' or 3' ends, they are resistant to exonuclease- mediated degradation and are presumably more stable than most linear RNAs in cells. CircRNAs have been categorized as noncoding RNA, but more recently, they have been shown to encode proteins [22-24]. Like many other alternative noncoding isoforms, the biological functions of most circRNAs are unclear, however they have benefited from the development of high-throughput sequencing technology, which has enabled large-scale studies on circRNAs in recent years. Subsequent studies revealed that the expression of circRNAs is developmentally regulated, tissue- and cell-type specific, and shared across the eukaryotic tree of life [25-27]. CircRNAs are emerging as a heterogeneous class of molecules involved in modulating gene expression by regulating transcription and protein and miRNA functions. Studies have shown that in the brain, where the level of circRNA is significantly higher, some circRNAs consist mainly of portions of the multi-exon 5' untranslated region (5'UTR), suggesting that functions of these multi-exon 5'UTR of genes and/or circRNA is new [28]. Increasing numbers of circRNAs function in the brain, including circPDE4B [29], circRNA-0044073 [30], and circHIPK3 [31], as well as in heart failure [32, 33], human cancer (Josh N, et al.) [34] and other diseases [35], suggesting that circRNAs are crucial functional molecules in mammals. Thus, studying the roles of circRNAs on the gut-brain axis is important. A forward chemical genetic screen revealed gut microbiota metabolites that modulate host physiology [36], and circRNAs were found to be degraded by RNase L when induced by poly(I:C) or infected by virus (Liu Y, et al.).

From these findings, we concluded that the gut microbiome may influence the expression of circRNAs, but experimental evidence for this is lacking. In our recent study, we showed that *circNF1-419* could regulate autophagy in over-expressing circNF1-419 transfected astrocytes, likely through PI3K-I/Akt-AMPK-mTOR and PI3K-I/Akt-mTOR signaling pathways. And an AAV packaging system (virus titer 1×10^{12}) over-expressing circNF1-419 in vivo showed autophagy enhancing activity by binding Dynamin-1 and AP2B1, delaying senile dementia by regulating aging markers (p21, p35/25, p16) and inflammatory factors (IL-6, IL-10, NF- κ B), and by reducing the expression of AD marker proteins Tau, p-Tau, $A\beta_{1-42}$, and APOE in SAMP8 mice [37]. Therefore in this study, we subjected data on the gut microbiota and circRNA sequences of brain tissues from AD-like mice to choice-based conjoint analysis. In addition, from the preventive medicine perspective. considering the effects of diet on health and the causes and processes of chronic disease formation, we also focused on the influence of circRNAs in the brain to the gut and gut microbiome. We aimed to identify more associations between gut microbiota and brain circRNAs. We also aimed to enlarge the 'microbiome-transcriptome' linkage library, which would provide more information on the interplay between gut and brain in order to aid in the identification of potential therapeutic markers and mechanistic solutions to complex problems commonly encountered in pathology, toxicology, and drug development studies.

RESULTS AND DISSCUSSION

Gut microbiota plays an important role in the circRNA sequences in AD-like mice

To understand the network of circRNAs acting on the microbiome-gut-brain axis, the gut microbiota (Supplementary Figure 1A–1B), serum metabolites (Supplementary Figure 2A–2B), and circRNA sequences of brain tissues (Supplementary Table 1) from 8-monthold APP/PS1 mice were subjected to choice-based conjoint analysis. The interactions of gut microbiota and metabolites are shown in Figure 1A–1B, which revealed that *Adlercreutzia* (Actinobacteria), *Streptococcus*, *Lactobacillus, Ruminococcus* and *Prevotella* may be the key bacteria regulating serum metabolites such as L-acetylcarnitine, 11-beta-hydroxyandrosterone-



Figure 1. The combined data analysis between gut microbiome and serum metabolome of APP/PS1 mice. (A) The Spearman correlation coefficient for each metabolite type and each bacterial genus, see also Supplementary Figure 1A–1B and Supplementary Figure 2A–2B. (B) Serum metabolome and genera. Red and blue indicate positive and negative correlations, see also Supplementary Figure 1A–1B and Supplementary Figure 1A–1B. The set of the most connections are highlighted in red. Data are presented as the means of more than 6 independent experiments.

3-glucuronide, phosphatidylethanolamine and phosphorus esters. With the gut microbiota and serum metabolite changes, there were 501 differentially expressed circRNAs in the model group (fold change > 1.50, p < 0.05 vs normal C57 mice, Figure 2A) up-regulated, and 624 circRNAs down-regulated, including chr14_ 84532875_ 84533695_+ (*Pcdh17*), chr1_140425193_ 140450304_+ (*Kcnt2*), chr8_94047272_ 94055344_+ (*Ogfod1*), chr3_158104428_ 158148699_- (*Lrrc7*), chr10_62633977_ 62643372_- (*Ddx50*), chr12_6960 3476_69607412_- (*Sos2*), chr12_85028770_85030887_+ (*Ylpm1*), chr10_93208172_93218089_+ (*Cdk17*), chr11_ 79546971_79551134_+ (*NF1*), and chr6_52609145_ 52630349_- (*Hibadh*); more details are shown in Supplementary Table 1, (PRJNA553830).

Given that the function of most circRNAs is unknown, the mRNA sequence was concurrently analyzed to offer an alternative explanation. Using RNA-sequencing, 347 genes were up-regulated and 507 genes were downregulated (fold change > 1.50, p < 0.05, Figure 2B) in brain tissues dissected from APP/PS1 double transgenic mice. The networks of Ingenuity Canonical Pathways (IPA) data showed that the diseases and functions of cellular movement, cell death and survival might be regulated by molecules in a network including 26s Proteasome, AGT, ALB, BCR (complex), BLNK, CA3, CASP1, CCND2, CD4, CDT1, CENPF, DAPK1, DIO2, DSP, EGR1, Focal adhesion kinase, FST, HGF, IgG, KDELR3, KIF22, LBX1, LY9, MAPK12, MMP19, NEU4, NOD2, P38 and MAPK, PRNP, RIN1, S100A8, S100A9, SDC1 and ST14; cell-to-cell signaling and interaction, nervous system development and function, cellular function and maintenance might be regulated by molecules in a network including Akt, Alp, CAMK2A, CAMK2N1, CCKBR, CHRM3, CLEC7A, CSF2RB, CYBB, EPHA4, ERK, FGF7, FLT3, FOSL2, Growth hormone, IL23, IRX1, KCNA5, KLF10, MAPK, MGLL, MIA, MMD, NPY, PLK2, PPP1R1B, RAG1, RGS4, RORC, SNCA, SPARC, STAT5a/b, TLR2, VEGF, WNT9A mRNAs (Supplementary Figure 3). Additional studies are needed in this area.

GO (gene ontology) enrichment analysis of differentially expressed circRNAs showed that they mainly influenced synaptic transmission, post-synapse, positive regulation of neurogenesis, single-organism behavior, protein serine/threonine kinase activity, histone modification, regulation of GTPase activity, and neuron death. KEGG enrichment analysis showed that they mainly influenced *MAPK*, *Rap1*, *cAMP*, glutamatergic synapse, neurotrophin and Rap1 signaling pathways. Reactome enrichment analysis of differentially expressed circRNAs showed that they mainly influenced developmental biology, signaling by Rho GTPases, neuronal system, signaling by NGF, axon guidance, signaling by EGFR, transmission across chemical synapses, NGF signaling via TRKA from the plasma membrane, organelle biogenesis and maintenance, and signaling by FGFR1~4. Bioinformatics analyses of circRNA and mRNA annotation, functional classification, functional enrichment and cluster analyses showed that the changes of gut microbiota and serum metabolites could influence the circRNA sequences and function. This conclusion requires additional evidence, particularly clinical sample support, and the mechanism remains poorly understood and needs further investigation.

In order to understand the connections between the gut microbiota and brain function, an additional experiment was carried out using fecal microbiota transplantation. Fecal samples were collected from 8-month-old APP/PS1 mice, PBS was added and the bacterial solution was concentrated immediately by centrifugation. C57 mice (9 months old) were treated with the bacterial solution by enema, for 3 weeks, after the mixture of antibiotics according to the method of de Groot PF, et al. [59]. Microbiome analysis of the 16S rRNA genes was performed after 3 months. Gut microbiota from the APP/PS1 mice settled in the normal mice (Figure 2C-2E), influenced the intestinal microenvironment (Figure 2F, H&E of intestine), and up-regulated the expression of Tau and $A\beta_{1-42}$ (Figure 2F) in the hippocampus. Together these results and those of our previous study demonstrating that the most highly abundant gut microbiota were correlated with the level of $A\beta_{1-42}$ [3], led us to summarize that the gut microbiota have some interactions with the circRNA sequences of the brain in AD-like mice, and targeting the gut microbiota might be a feasible and effective strategy for ameliorating the symptoms or even delaying the progression of AD. Thus the gut microbiota plays an important role in the progression of AD.

CircNF1-419 changes the intestinal physiology and gut microbiota in SAMP8 mice

Recently, a report demonstrated that avian leucosis virus targets circ-Vav3 and then sponges gga-miR-375 to promote epithelial-mesenchymal transition [38], indicating that a microorganism could directly influence the formation, expression and function of circRNAs, and the mysterious of circRNA is suggested in increasing numbers of studies [30, 38, 39]. In order to verify these, the expression level of circRNAs was examined by qRT-PCR in AD-like mice (PCR primers are listed in Table 1). The circRNAs of *circ_zfyve1-504*, *circ_zchc11-811*, *circ_zfp652-1147*, *circ_zfp236-1257*, *circNF1-419* and *circ_zranb1-1575* were differentially expressed (Figure 3A), suggesting that these circRNAs may be related to AD. We then over-expressed *circNF1-419* and *circ_0001239* in the animal brain



Figure 2. (A) Differentially expressed circRNAs in the APP/PS1 double transgenic mice brain samples (fold change > 1.50, p < 0.05 vs normal C57 mice, n=3). (B) Differentially expressed mRNAs in the APP/PS1 double transgenic mice brain samples (fold change > 1.50, p < 0.05 vs normal C57 mice, n=3). (C) Rarefaction curves based on OTU. The structure at the (D) phylum and (E) genus levels. (F) Histopathological changes in the brain identified using H&E staining and biomarker expression of Tau and $A\beta_{1-42}$ using immunohistochemical methods after fecal microbiota from six months APP/PS1 mice transplantated into 9 months old C57 mice, (n≥6).

Table 1. PCR primers.

| Primer name | Sequence (5'->3') | Product size (bp) |
|--------------------------|--|-------------------|
| β-actin | β-actin-F1: GCTTCTAGGCGGACTGTTAC β-actin-R1: CCATGCCAATGTTGTCTCTT | 100 |
| Circ-Zfyve1 | Circ-Zfyve1-F1: 5'- tcagcttctgggttctggtaaca-3' Circ-Zfyve1-R1: 5'- gtgtgtgagactttccatcacc-3' | 123 |
| Circ-Zranb1 | Circ-Zranb1-F2: 5'- gttattaagcacaagatctgc-3' Circ-Zranb1-R2: 5'- gctgcttgctgagataccttt-3' | 135 |
| Circ-Zechell | Circ-Zcchc11-F1: 5'- cagcagatgatttgatttgc-3' Circ-Zcchc11-R1: 5'- atattcttctttggttcatg-3' | 159 |
| Circ-Zfp652 | Circ-Zfp652-F1: 5'- agcacatgaacgttactcac-3' Circ-Zfp652-R1: 5'- cttggagcatcttgtctgaatg-3' | 131 |
| Circ-Zfp236 | Circ-Zfp236-F3: 5'- tccccgttcctacctggcca-3' Circ-Zfp236-R3: 5'- cgggctcagacagttccaga-3' | 140 |
| nmu_circ_0000705 | circ_0000705-F1: 5'-tcaagatgaagtcgttcccac-3' circ_0000705-R1: 5'-acattctctctcggtgcttg-3' | 143 |
| nmu_circ_0000705 | circ_0000705-F2: 5'-gaacatgtgcgcatggtggac-3' circ_0000705-R2: 5'-gctgtcgtgggaacgacttc-3' | 164 |
| nmu_circ_0008590 | circ_0008590-F1: 5'-caggggcaggatcagaacgc-3' circ_0008590-R1: 5'-ctgtctcgttcgttcctccac-3' | 160 |
| nmu_circ_0008590 | circ_0008590-F2: 5'-cgtccgccaagtcatcagat-3' circ_0008590-R2: 5'-cttgtcggtgcgttctgatc-3' | 141 |
| nmu_circ_0012931 | circ_0012931-F1: 5'-tccacttgttaagatacetc-3' circ_0012931-R1: 5'-gcaagagtagatacataattcc-3' | 168 |
| nmu_circ_0012931 | circ_0012931-F2: 5'-tatgaacatcatcacaggtc-3' circ_0012931-R2: 5'-gcataactaatctgaggtatetta-3' | 226 |
| hr10:108583875-108691063 | chr10:108583875-108691063-F1: 5'-tgggtggcttatctttccgc-3' chr10:108583875-108691063-R1: 5'-gaaggtagtatactcacatggg-3' | 211 |
| hr10:108583875-108691063 | chr10:108583875-108691063-F2: 5'-ttcatagcaagagaaactgg-3' chr10:108583875-108691063-R2: 5'-ttggttcaagcggaaagata-3' | 139 |
| hr15:39566944-39616510 | chr15:39566944-39616510-F1: 5'-actcagccaaaccgtgctat-3' chr15:39566944-39616510-R1: 5'-ctagtagcttcatatgatcgac-3' | 170 |
| hr15:39566944-39616510 | chr15:39566944-39616510-F2: 5'-tgctcactggagaagaatga-3' chr15:39566944-39616510-R2: 5'-tctatatccatagcacggtt-3' | 172 |
| hr4:43091229-43115160 | chr4:43091229-43115160-F1: 5'-ctgccgcccagtgtttaaat-3' chr4:43091229-43115160-R1: 5'-gaccatgatggaatgtgtagac-3' | 159 |
| hr4:43091229-43115160 | chr4:43091229-43115160-F2: 5'-actaaaatattcagtgtgtaactt-3' chr4:43091229-43115160-R2: 5'-tatgtgttaaatttaaacactg-3' | 175 |
| 3-actin | β-actin-F1: AGGGAAATCGTGCGTGACAT β-actin-R1:GAACCGCTCATTGCCGATAG | 150 |
| Cir- SIRT1-623 | Cir- SIRT1-623-F3: GAGCAGGTTGCAGGAATCCA Cir- SIRT1-623-R3: ACAAAAGTATATGGACCTGA | 136 |
| Cir- SIRT1-395 | Cir- SIRT1-395-F2: TTCAAGTTTGCAAAGGTCCA Cir- SIRT1-395-R2: AATCTGCCACAGTGTCATAT | 137 |
| Cir-CTGF-212 | Cir-CTGF-212-F1: CTAGAGGAAAACATTAAGCCT Cir-CTGF-212-R2: ACAGGTCTTAGAACAGGCG | 116 |
| mo_circ_003172 | rno_circ_003172-F2: GTCCACACTCCGGGATGAG | 165 |
| rno circ 002671 | <pre>rno_circ_003172-R2: AGCTCGTCCTTCACTGCGC rno_circ_002671-F1: CCACCAACAGATTCAGGAA</pre> | 129 |

| | rno_circ_002671-R1: CTCTTGAGTATCTGGTTCTG | |
|------------------|--|-----|
| rno_circ_002276 | rno_circ_002276-F1: ACAAGAAGCTTGCTCAGGTC rno_circ_002276-R1: ATGTTCTGTGGCTCCTTGCT | 163 |
| rno_circ_001216 | rno_circ_001216-F2: GGTGCCTCCAAGGAGGTG rno_circ_001216-R2: ACACACCGCCATGCAGTACTC | 171 |
| rno_circ_001215 | rno_circ_001215-F2: GCGGTGCCTCCAAGGTTCC rno_circ_001215-R2: ACGGCCTTCTTGTCAGCTTTGG | 217 |
| rno_circ_000987 | rno_circ_000987-F2: CTGGTGTCAAGTAAGGTATT rno_circ_000987-R2: TGAATAGAAGGGTACATCTG | 181 |
| rno_circ_NF1-419 | rno_circ_NF1-419-F2: AGTCGAATTTCTACAAGCTTC rno_circ_NF1-419-R3: AGCTTCTCCAAATATCCTCAT | 179 |
| | | |

using an adeno-associated virus (AAV) system, with the aim of identifying possible connections.

First, we utilized our previous designed AAV viral transduction system with RNA interference (sicircNF1-419) and separately an over-expressing *circNF1-419* (sscircNF1-419) (Supplementary Figure 4). Two microliters of the AAV packaging system (virus titer 1 \times 10¹²) were injected into the cerebral cortex of SAMP8 mice. Statistical analysis of the 16S rRNA gene sequencing data showed that sscircNF1-419 can significantly change the gut microbiota composition of the SAMP8 mice 7 weeks after infection - the relative abundance of Bacteroidetes, Actinobacteria, Deferribacteria and Cyanobacteria were increased (Figure 3B, p < 0.05 vs SAMP8 group) at the phylum level, and the relative abundance of *Bacteroides*, Alloprevotella, Lactobacillus, Lachnoclostridium and *Ruminiclostridium* 9 were changed (Figure 3B, p < 0.05vs SAMP8 group) at the genus level. Previous studies indicated that people who eat plenty of protein and animal fats have predominantly Bacteroides bacteria, while for those who consume more carbohydrates, *Prevotella* species dominate, which is due to the fact that the main sources of energy for *Bacteroides* species in the gut are complex host-derived and plant glycans [40]. Studies have revealed that the presence of Prevotella in the human gastrointestinal tract is inversely correlated with Parkinson's disease [41, 42], and members of the family Lachnospiraceae could protect against colon cancer in humans by producing butyric acid with the functions of anti-inflammation and immunomodulation [43]. Histopathological observations showed that circNF1-419 could improve the damage of intestinal tissues in SAMP8 mice and 12month-old mice (Figure 4A), expression of AChE and AMP, CHRNB1 and CHRNA1 in the brain were improved (Figures 4C-4D), and expression of NF- κ B p65 was activated (Figure 19B, p < 0.05). This all indicated that *circNF1-419* in the brain could improve the central cholinergic system and improve intestinal physiology in AD-like mice.

CircNF1-419 changes the gut microbiota genetic trajectory in newborn KM mice

To elucidate how *circNF1-419* in the brain influences the gut microbiota, we hypothesized that new discoveries could be found via monitoring the colonization of gut microbiota in newborn KM mice. Two microliters of the AAV (over-expressing *circNF1-419*) packaging system (virus titer 1×10^{12}) were injected into the cerebral cortex of 2-week-old KM mice, whose mother was fed with standard diet or the HSHF diet.

Histopathological observations showed that *circNF1-419* could improve the damage of intestinal tissues in mice fed with the HSHF diet (Figure 4A). 16S rRNA gene sequencing revealed that the relative abundance of Bacteroidetes, Actinobacteria, Deferribacteria and Cyanobacteria were changed (p < 0.05 vs normal group, Figure 4B) at the phylum level, and the relative abundance of Bacteroidales S24-7 group, Lachnospiraceae NK4A136 group. Alistipes, Alloprevotella, Lachnospiraceae. Bacteroides, Desulfovibrio, Lactobacillus, Roseburia and *Helicobacter* were changed (p < 0.05 vs normal group,Figure 4C) at the genus level 8 weeks after infecting with the AAV. The expression of AChE and AMP, CHRNB1 and CHRNA1 were improved (Figure 3E, p < 0.05). Additional findings were that interference of circNF1-419 aggravates some initial bacteria imbalance, including abundance increasing the of Actinobacteria, Deferribacteres, Proteobacteria while decreasing the Firmicutes (Figure 4B-4C), and circNF1-419 could improve these changes. This indicated that the gut microbiota had notable correlation with the host, and this certainly included the circRNAs.

Association analysis of *circNF1-419*, intestinal transcriptome and gut microbiota

To understand how *circNF1-419* influences the gut microbiota, we integrated analysis of the association between gut microbiota (Figure 3B and 4C) and



Figure 3. CircRNA NF1-419 influences the gut microbiota composition and cholinergic system. (A) The circRNAs of circ_zfyve1-504, circ_zcchc11-811, circ_zfp652-1147, circ_zfp236-1257, circNF1-419 and circ_zranb1-1575 by reverse transcription polymerase chain reaction in Ganoderma lucidum extractions (LZ) (oral LZ of 50 mg/[kg·d]) and Hericium erinaceus extractions (HE) (oral HE of 50 mg/[kg·d]) treated SAMP8 mice brain samples lasting 24 weeks. (**B**) Over expression of *circNF1-419* in brain could change the gut microbiota at phylum (a) and genus level (b) of SAMP8 mice, see also in Supplementary Figure 8. (**C**) Expression of the proteins AChE, AMP, CHRNA1 and CHRNB1 in the brain tissues of SAMP8 mice after infection of over-expressing *circNF1-419* AAV. (**D**) Expression of the proteins AChE, AMP, CHRNA1 and CHRNB1 in the brain tissues of 12-month-old mice after infection of over-expressing *circNF1-419* AAV. (**E**) Expression of the proteins AChE, AMP, CHRNA1 and CHRNB1 in the brain tissues of 2-month-old mice after infection of over-expressing *circNF1-419* AAV. (**E**) Expression of the proteins AChE, AMP, CHRNA1 and CHRNB1 in the brain tissues of 2-month-old mice after infection of over-expressing *circNF1-419* AAV. Data are presented as the means ± SD of more than 8 independent experiments, and more than 3 independent experiments in Western bolting. **p* <0.05 and ***p* <0.01 *vs.* the model group by one-way ANOVA, followed by the Holm-Sidak test.

differential expression mRNAs of the small intestine tissue (Supplementary Figure 5A-5B) on the circNF1-419 treated SAMP8 and KM mice. As shown in Figure 3, circNF1-419 in the brain mainly influences the Candidatus Arthromitus, Lachnospiraceae bacteria FCS020 Lachnospiraceae UCG-006, group, and [Eubacterium] xylanophilum group, and the mRNAs of Gal3st1 (galactose-3- O-sulfotransferase 1), Gamt (guanidinoacetate methyltransferase), Gpr62 (G proteincoupled receptor 62), and Opalin (oligodendrocytic myelin paranodal and inner loop protein). The relative abundance of those bacteria shown in Figures 3B and 4C, and the expression of mRNAs shown in Supplementary Figure 5A-5B, indicated that circNF1-419 in the brain plays a role on multiple targets in the intestine, but how circNF1-419 influences these mRNAs and the gut microbiota still needs considerable work on their metabolomics, signaling pathways and electrophysiology.

The mRNAs of brain tissue showed that the expression of GABRA1, GABRA6, St6galnac4, St8sia5, Pde9a, Tmem132a, Tmem163, Tmem62 and Tmem63c (Figure 5A and 5B) were up-regulated after over-expressed *circNF1-419* in brain, which indicated that the central immune system were activated, in other words that *circNF1-419* could activated central immune to improve the symptoms of AD, but need much more further study. And the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of 16S functional gene prediction analysis using PICRUSt also showing altered signaling pathways (Figure 5C) and the network (Figure 5D). Although the function and signaling pathway need much more studies.

Circular RNA *circ_0001239* changes the gut microbiota genetic trajectory in mice

Additionally, we designed another AAV viral transduction system with RNA over-expressing mmu circ 0001239 (ZCCHC11, Supplementary Figure 6). The function of this circRNA in the brain was unknown but its expression was increased in the APP/PS1 and SAMP8 mice (Figure 4A). Two microliters of the AAV packaging system (virus titer 1×10^{12}) were injected into the cerebral cortex of 7-day-old mice. After 3 months continuous infection, the gut microbiota



Figure 4. CircNF1-419 changes the gut microbiota genetic trajectory in newborn KM mice. (A) Intestinal physiology changes after infection of over-expressing *circNF1-419* AAV. (B) Heatmap of gut microbiota *in fimo* at phylum level after infection of over-expressing *circNF1-419* AAV. (C) Heatmap of gut microbiota *in fimo* at genus level after infection of over-expressing *circNF1-419* AAV in young mice. (C) Heatmap of gut microbiota *in fimo* at genus level after infection of over-expressing *circNF1-419* AAV in young mice. Data are presented as the means \pm SD of more than 8 independent experiments. *p <0.05 and **p <0.01 *vs.* the model group by one-way ANOVA, followed by the Holm-Sidak test.



Figure 5. Association analysis of *circNF1-419*, **intestinal transcriptome and gut microbiota.** Influences on the expression of GABRA1, GABRA6, St6galnac4, St8sia5, Pde9a (A), Tmem132a, Tmem163, Tmem62 and Tmem63c (B) in brain tissues. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of 16S functional gene prediction analysis using PICRUSt also showing altered signaling pathways (C) and the network (D). Data are presented as the means of more than 8 independent experiments, see also in Supplementary Figure 4.



Figure 6. *Circ0001239* changes the gut microbiota genetic trajectory in new born mice. (A) The alpha diversity (A) and beta diversity (B) of the gut microbiota when the *circ0001239* over expressed in brain, see also in Supplementary Figure 6. (C) The ternary phase diagram showed that the most of the bacteria were closed to the *circ_0001239* group. (D) The relative abundance of different bacteria when the *circ0001239* over expressed in brain (*LDA* < 3.5). Data are presented as the means \pm SD of 8 independent experiments. *p <0.05 and **p < 0.01 vs. the model group by one-way ANOVA, followed by the Holm-Sidak test.



mmu_circ_0001239-CY3: ctttaggcaagcaaatcaaatcatetg



Different expression of mRNA after treated with circZCCHC11-AAV

| Gene symbol | circZCCHC | circZCCHC | circZCCHC | Control | Control | Control | FDR | log2FC | Regulated |
|----------------------------|-----------|-----------|-----------|---------|---------|---------|----------|----------|-----------|
| Rgcc | 23.87 | 15.19 | 11.84 | 34.83 | 37.80 | 35.16 | 0.008531 | 1.067891 | up |
| Ly6e | 26.26 | 47.21 | 23.47 | 78.90 | 98.84 | 76.61 | 0.000414 | 1.313757 | up |
| Gtpbp8 | 5.23 | 6.54 | 4.45 | 2.84 | 2.95 | 3.57 | 0.009797 | -1.24615 | down |
| Inha | 0.84 | 0.70 | 0.65 | 5.72 | 3.74 | 5.52 | 1.25E-07 | 2.742711 | up |
| Rpsa-ps10 | 151.46 | 134.35 | 88.51 | 16.39 | 20.25 | 16.88 | 1.79E-09 | -2.82068 | down |
| Hspa2 | 0.34 | 0.95 | 9.06 | 17.22 | 18.58 | 18.75 | 1.24E-05 | 2.353344 | up |
| Gm8730 | 1.17 | 1.06 | 1.26 | 46.14 | 47.63 | 49.50 | 2.01E-72 | 5.328373 | up |
| Lrrc61 | 3.22 | 4.33 | 2.45 | 7.65 | 6.25 | 7.37 | 0.000971 | 1.438576 | up |
| Pcdha8 | 0.30 | 0.25 | 0.58 | 0.00 | 0.00 | 0.00 | 1.96E-07 | -INF | down |
| Mus_musculus_newGene_16461 | 0.51 | 0.37 | 0.55 | 0.14 | 0.10 | 0.00 | 0.001554 | -2.56059 | down |
| Mus_musculus_newGene_21123 | 0.34 | 0.15 | 0.10 | 0.98 | 0.82 | 0.93 | 0.004235 | 2.180961 | up |
| Mus_musculus_newGene_27705 | 0.29 | 0.40 | 0.54 | 0.12 | 0.00 | 0.00 | 0.000205 | -3.33901 | down |
| Mus_musculus_newGene_32867 | 1.16 | 1.61 | 2.76 | 0.69 | 0.28 | 0.33 | 0.006132 | -2.31418 | down |
| Mus_musculus_newGene_36228 | 0.39 | 0.27 | 0.35 | 2.58 | 2.65 | 2.50 | 1.23E-09 | 2.778418 | up |
| Mus_musculus_newGene_4054 | 0.24 | 0.20 | 0.24 | 7.17 | 7.51 | 7.60 | 8.09E-22 | 4.983948 | up |
| Mus_musculus_newGene_4258 | 1.48 | 0.59 | 0.81 | 0.0073 | 0.0011 | 0.0039 | 9.25E-07 | -6.97056 | down |
| Mus_musculus_newGene_5451 | 19.44 | 20.08 | 19.70 | 133.18 | 130.86 | 143.10 | 3.71E-31 | 2.761705 | up |

Figure 7. Effects of over expressing *circ_0001239* on KM mice brain. (A) Nile red (red) and DAPI (blue) staining of BV2 cells bearing ss-ctrl or ss-circ0001239. Representative of three independent experiments. (B) MiRNA levels in over expressing *circ_0001239* KM mice brain samples. Representative of three independent experiments. (C) Differently expressed mRNA in over expressing *circ_0001239* KM mice brain samples. Representative of three independent experiments.

composition was detected using 16S rRNA gene sequencing. The results revealed that *circ* 0001239 can change the alpha diversity (Figure 6A) and beta diversity (Figure 6B) of the gut microbiota. The ternary phase diagram showed that the most of the bacteria were closed to the *circ_0001239* group (Figure 6C), and the relative abundance of different bacteria is shown in Figure 6D (LDA < 3.5), for example increases in the *Lachnospiraceae* NK4B4 group, *Lachnospiraceae* and *Lactobacillus*, which indicated that over-expression of *circ_0001239* in the brain could change the genetic trajectory of the gut microbiota.

The miRNA and mRNA sequences of brain tissues from the *circ_0001239*-treated mice showed that expression of mmu-miR-452-5p, let-7j and miR-205-5p were downregulated (Figure 7A, $|log2(FC)|\geq 1$, FDR ≤ 0.05) compared to the control, and there were 10 mRNAs upregulated while seven were down-regulated (Figure 7B). Most previous studies on miR-452-5p [44, 45], let-7 [46, 47] and miR-205-5p [48, 49] focused on cancers. KEGG analysis of the mRNA sequences indicated that overexpression of *circ_0001239* in the brain mainly influences the ribosome and proteoglycans in cancer pathways, suggesting that *circ_0001239* has the sponge miRNA function and mediates a series of chain reactions in the brain, then influences gut function and microbiome engraftment from their parent.

CONCLUSIONS

This study revealed that the gut microbiome could influence the expression of some circRNAs in the brain, and reverse experiments indicated that over-expression of some circRNAs in the brain can influence the gut microbiota composition and their heredity to the descendant. As, over-expression of *circNF1-419* in the brain using an AAV viral transduction system, altered the gut microbiota structure and intestinal homeostasis. These results are the first demonstration of a link between circRNAs and the gut microbiome. They enlarge the 'microbiome-transcriptome' linkage library, providing more information on the interplay between gut and brain to aid in the identification of potential therapeutic markers and mechanistic solutions to complex problems commonly encountered in pathology, toxicology, and drug development studies. Additional studies will be required on these complex interaction systems.

MATERIALS AND METHODS

Animals

Male SAMP8 mice (5 months old, mean body weight 20 \pm 5 g) were purchased from Beijing HFK Bioscience Co., LTD (Certificate No: SCXK [Jing] 2014-0004), and adult

KM mice (18-22 g, 16 female and 8 male, 8 weeks old) were obtained from Center of Laboratory Animal of Guangdong Province, SCXK [Yue] 2008-0020, SYXK [Yue] 2008-0085). All the mice pair-housed in plastic cages in a temperature-controlled ($25 \pm 2^{\circ}$ C) colony room with a 12/12-h light/dark cycle. The animals had free access to food and water. All experimental protocols were approved by the Center of Laboratory Animals of the Guangdong Institute of Microbiology. All efforts were made to minimize the number of animals used. All animals were allowed to acclimate for at least 1 week prior to the initiation of the experiments.

Then, SAMP8 mice were randomly allocated into 3 groups of 8 animals each: SAMP8 model group, sscircNF1-419-OV-AAV infected group, and sicircNF1-419-OV-AAV infected group, two μ l of the AAV packaging system (virus titer 1 × 10¹²) were injected into the cerebral cortex.

The female KM mice were randomly allocated into 2 groups of 8 animals each, one fed with high sugar & fat diet, and the other fed with standard diet. A month later, the female mice were randomly re-allocated into groups of 2 animals each and one male mice, keep feeding the original diet to the end of pregnancy, then all the mice fed with standard diet. After births one week, two μ l of the AAV packaging system (virus titer 1 × 10¹²) were injected into the brain.

Balb/c mice were obtained from the Center of Laboratory Animals of Guangdong Province of China, (SCXK [Yue] 2008-0020, SYXK [Yue] 2008-0085), conventional breeding to 12 months old, two μ l of the AAV packaging system (virus titer 1 × 10¹²) were injected into the cerebral cortex.

Histopathology and immunostaining

The brain, colon tissues were removed and fixed in the 4% paraformaldehyde at pH 7.4 for further pathological observation. These tissue samples were made into paraffin sections after drawing materials, fixation, washing, dehydration, transparency, dipping in wax, and embedding. Obesity related parameters or other related pathologic changes were measured. The brains of animals were dissected. A total of four brains from each group were fixed in 4% paraformaldehyde solution and prepared as paraffin sections. Sections were stained with hematoxylin-eosin (H&E).

Microbiome analysis

Fresh intestinal content samples were collected before the fasting of the rats for 12 hour and stored at -80 °C. Microbial DNA isolated from the samples, with total

masses ranging from 1.2 to 20.0 ng, were stored at -20 °C. The microbial 16S rRNA genes were amplified using the forward primer 5'-ACTCCTACG GGAGGCAGCA-3' and the reverse primer 5'-GGA CTACHVGGGTWT CTAAT-3', and the rat forward primer 5'-CCTAYGGGR BGCASCAG-3' and reverse primer 5'-GGACTACN NGGGTATCTAAT-3'. Each amplified product was concentrated via solid-phase reversible immobilization and quantified by electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). After NanoDrop quantification of DNA concentration, each sample was diluted to a concentration of 1×10^9 molecules/µl in TE buffer and pooled. 20µl of the pooled mixture was sequenced on an Illumina MiSeq sequencing system (Illumina Inc, San Diego, CA, USA) according to the manufacturer's instructions.

Metabolomic analysis

After the water maze testing, the serum was acquired. 80 µL serum were added into 240 µL of cold mixture methanol with acetonitrile (2:1, v/v), and 10 μ L internal tagging standard (L-2-chlorine-phenylalanine, 0.3 mg/mL, dissolved in methanol) were added, vortex after 2 min, then extracted using ultrasonic extraction method for 5 min. After 20 min standing at -20 °C, centrifuge for 10 min at low temperature (14000 prm, 4 °C), 200 uL of supernatant loaded into a sample bottle with lining tube for LC - MS analysis (Waters UPLC I-class system equipped with a binary solvent delivery manager and a sample manager, coupled with a Waters VION IMS Q-TOF Mass Spectrometer equipped with an electrospray interface (Waters Corporation, Milford, USA). LC Conditions: Column: Acquity BEH C18 column (100mm \times 2.1mm i.d., 1.7µm; Waters, Milford, USA). Data analysis as described previously (Han, et al.).

RNA isolation and sequencing

Total RNA was isolated using Qiazol and miRNeasy Kits, including additional DNase I digestion. Then remove the ribosomal RNA using Ribo-ZeroTM Magnetic Gold Kit, enzymatic degradation of linear RNA using Rnase R enzyme. Add fragmentation buffer to be fragments, synthesize the first chain of cDNA with six bases random hexamers, then the buffer, dNTPs, RNase H and DNA polymerase I to synthesize the second chain of cDNA. Purification uing QiaQuick PCR kit and elution using EB buffer after terminal repairing, processing bases A, add sequencing joint. For next generation sequencing, 0.5 µg ribosomal RNAdepleted RNA was fragmented and primed. The sequencing libraries were constructed using Illumina TruSeq RNA Sample Preparation Kits and were sequenced by Illumina HiSeqTM 2500 flowcell.

The bioinformatics analysis of RNA annotation, functional classification, functional enrichment and cluster analyses were performed [47, 50, 51].

Computational analysis of circRNAs

The reads were first mapped to the latest UCSC transcript set using Bowtie2 version 2.1.0 [52] and the gene expression level was estimated using RSEM v1.2.15 [53]. For lincRNA expression analysis, we used the transcripts set form Lncipedia (http://www. Incipedia.org). TMM (trimmed mean of M-values) was used to normalize the gene expression. Differentially expressed genes were identified using the edgeR program [54]. Genes showing altered expression with p < 0.05 and more than 1.5 folds changes were considered differentially expressed. The pathway and network analysis were performed using Ingenuity (IPA). IPA computes a score for each network according to the fit of the set of supplied focus genes. These scores indicate the likelihood of focus genes to belong to a network versus those obtained by chance. A score > 2 indicates a <= 99% confidence that a focus gene network was not generated by chance alone. The canonical pathways generated by IPA are the most significant for the uploaded data set. Fischer's exact test with FDR option was used to calculate the significance of the canonical pathway.

For circRNA expression analysis, the reads were to mapped genome using the STAR [55] and DCC [56] was used to identify the cirRNA and to estimate the circRNA expression. TMM (trimmed mean of Mvalues) was used to normalize the gene expression. Differentially expressed genes were identified using the edgeR program. miRanda [57] was used to predict the miRNA target of the circRNA. R was used to generate the figure.

CircRNA verification by quantitative real-time polymerase chain reaction (qRT-PCR)

To validate the reliability of high-throughput RNA sequencing and to explore the expression of circRNAs during aging, the expression levels of circRNAs were examined by qRT-PCR. With reference to Memczak's method [58], two sets of primers for each circRNA were designed using Primer Express software version 5.0 (Table 1): an outward-facing set which was expected to amplify only the circRNA, and an opposite-directed set to amplify the linear form.

Total RNA was extracted (TRIzol[®] Reagent, Life technologies), digested using RNase R, and purified. cDNA was synthesized using a Geneseed[®] II First Strand cDNA Synthesis Kit (Geneseed, USA).

Outward-facing primers were designed to amplify the fragment across the junction from cDNA, then the fragment was sequenced by Sangon Biological Engineering Company (Shanghai China). QRT-PCR was performed using Geneseed[®] qPCR SYBR[®] Green Master Mix (Geneseed, USA), and PCR-specific amplification was conducted with an ABI 7500 (Applied Biosystems, USA). The expression of circRNAs was defined based on the threshold cycle (Ct), and relative expression levels were calculated via the $2^{-\Delta\Delta Ct}$ method. GAPDH served as an internal standard control with all reactions performed in triplicate.

Western bloting analysis

Global brain tissue was dissected from treated mice (purchased from the Beijing HFK Bioscience Co., LTD [Certificate No: SCXK (Jing) 2014-0004]) and proteins extracted with radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo ScientificTM T-PERTM Tissue Protein Extraction Reagent, 78510). The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. After blocking with 5% nonfat dry milk in Tris-buffered saline (20 mM Tris-HCl, 500 mM NaCl, pH 7.4) with 0.2% Tween-20 (Aladdin, T104863), the membranes were probed with antibodies overnight at 4°C, followed by incubation with a horseradish peroxidase-conjugated goat anti-mouse (Servicebio, G2211-1-A) or goat anti-rabbit (Servicebio, G2210-2-A) IgG secondary antibody (1:2000). The antibodies were as follows; anti-Abeita A4, -APOE, -BACE1, -p53 (abcam, 66064), -p16 (Affinity, AF0228), -p21, -p-Tau-396, -TNF-α (abcam, 9739), -p-Tau-202, obtained from Affinity as well as GAPDH (CST, 2118L) and β -Actin (CST, 4970S). Band intensity was quantified using ImageJ software (NIH).

Statistical analysis

All data are described as the means \pm standard deviations (SD) of at least three independent experiments. The significant differences between treatments were analyzed by one-way analysis of variance (ANOVA) test at p < 0.05 using statistical package for the social sciences (SPSS, Abacus Concepts, Berkeley, CA, USA) and Prism 5 (GraphPad, San Diego, CA, USA) software.

Ethics approval

The animal protocols used in this work were approved by the Institutional Animal Care and Use committee of the Center of Laboratory Animals of the Guangdong Institute of Microbiology.

Study limitations

There are several strengths with this study, but there are also limitations. For example, the study lacks a rescue test with single bacteria, so we have not identified the one-on-one contact between circNF1-419 and single bacteria, and therefore could not find the signaling pathway or linking ligament. Using targeted strains in germ-free mice with multi-omics studies to reveal the interaction of circNF1-419 on the microbiome-gut-brain axis, or using knock-out circNF1-419 mice are needed in the future for positive validations.

AUTHOR CONTRIBUTIONS

All the authors designed this study; Chen DL wrote the manuscript; Chen DL and Guo YR carried out the computational analyses; Chen DL, Guo YR, Qi LK, Lai GX and Liu YD collected animal physiological data and fecal samples, extracted ruminal DNA, did the physiological and biochemical indexes measurement; Tang XC, Guo YR and Zhu XX did the western bolting analysis; Qi LK, Zeng M and Feng JX did the metabolomic analysis; Chen DL, Guo YR, Qi LK and Shuai O collected data regarding the microbial metabolic networks and transcriptome analysis; Xie YZ, BB. Yang and Wu QP helped to design the study and to develop the multi-omics analysis methods, reviewed this manuscript and offer all the necessary research start-up fund, experimental platform. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

We would like to thank Zhang Maolei for helpful advises in the preparation of this study. Sequencing services were provided by Guangzhou Geneseed Biotech Co.,Ltd. Guangzhou, and Personal Biotechnology Co., Ltd. Shanghai, China.

FUNDING

The present work was supported by the financial support from the National Natural Science Foundation of China (81701086), the Guangzhou Science and Technology Plan Projects ((201604016050, 201707020022), Natural Science Foundation of Hunan (2019JJ50631), GDAS' Project of Science and Technology Development (2019GDASYL-0104007).

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

 Smith PA. The tantalizing links between gut microbes and the brain. Nature. 2015; 526:312–14. <u>https://doi.org/10.1038/526312a</u> PMID:<u>26469024</u>

 Quigley EM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017; 17:94. <u>https://doi.org/10.1007/s11910-017-0802-6</u> PMID:<u>29039142</u>

 Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, Shuai O, Zhou G, Xie Y, Wu Q. Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer's disease in rodent models by targeting the microbiota- gut-brain axis. Front Aging Neurosci. 2017; 9:403.

https://doi.org/10.3389/fnagi.2017.00403 PMID:29276488

- Carneiro G, Zanella MT. Obesity metabolic and hormonal disorders associated with obstructive sleep apnea and their impact on the risk of cardiovascular events. Metabolism. 2018; 84:76–84. <u>https://doi.org/10.1016/j.metabol.2018.03.008</u> PMID:<u>29534971</u>
- Borges BC, Garcia-Galiano D, da Silveira Cruz-Machado S, Han X, Gavrilina GB, Saunders TL, Auchus RJ, Hammoud SS, Smith GD, Elias CF. Obesity-induced infertility in male mice is associated with disruption of Crisp4 expression and sperm fertilization capacity. Endocrinology. 2017; 158:2930–43. <u>https://doi.org/10.1210/en.2017-00295</u> PMID:<u>28911169</u>
- Embury CM, Wiesman AI, Proskovec AL, Heinrichs-Graham E, McDermott TJ, Lord GH, Brau KL, Drincic AT, Desouza CV, Wilson TW. Altered brain dynamics in patients with type 1 diabetes during working memory processing. Diabetes. 2018; 67:1140–48. <u>https://doi.org/10.2337/db17-1382</u> PMID:<u>29531139</u>
- DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014; 10:364–76. <u>https://doi.org/10.1038/nrendo.2014.44</u> PMID:<u>24732974</u>
- Roche SL, Silversides CK. Hypertension, obesity, and coronary artery disease in the survivors of congenital heart disease. Can J Cardiol. 2013; 29:841–48. https://doi.org/10.1016/j.cjca.2013.03.021 PMID:23688771
- 9. Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015; 19:361–79.

https://doi.org/10.1016/j.cld.2015.01.012 PMID:<u>25921668</u>

- Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015; 48:923–30. <u>https://doi.org/10.1016/j.clinbiochem.2015.06.023</u> PMID:<u>26151226</u>
- Gajic-Veljanoski O, Papaioannou A, Kennedy C, Ioannidis G, Berger C, Wong AK, Rockwood K, Kirkland S, Raina P, Thabane L, Adachi JD. CaMos Research Group. Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicenter osteoporosis study. BMC Geriatr. 2018; 18:4.

https://doi.org/10.1186/s12877-017-0692-0 PMID:<u>29304836</u>

PMID:24935119

- 12. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014; 10:455–65. https://doi.org/10.1038/nrendo.2014.94
- Rogers CJ, Prabhu KS, Vijay-Kumar M. The microbiome and obesity-an established risk for certain types of cancer. Cancer J. 2014; 20:176–80. <u>https://doi.org/10.1097/PPO.000000000000049</u> PMID:24855004
- Chan PC, Wei CY, Hung GU, Chiu PY. Reduced vascular risk factors in Parkinson's disease dementia and dementia with Lewy bodies compared to Alzheimer's disease. Brain Behav. 2018; 8:e00916. https://doi.org/10.1002/brb3.916 PMID:29541536
- Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, Deng L, Bry L, Gordon JI, Kahn CR. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metab. 2015; 22:516–30. <u>https://doi.org/10.1016/j.cmet.2015.07.007</u> PMID:26299453
- Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015; 17:120. <u>https://doi.org/10.1007/s11886-015-0671-z</u> PMID:26497040
- Rosenbaum M, Knight R, Leibel RL. The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab. 2015; 26:493–501. <u>https://doi.org/10.1016/j.tem.2015.07.002</u> PMID:<u>26257300</u>
- Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013; 34:39–58.

https://doi.org/10.1016/j.mam.2012.11.001 PMID:23159341

- 19. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013; 29:79–84. <u>https://doi.org/10.1097/MOG.0b013e32835a4b3e</u> PMID:<u>23041678</u>
- Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015; 3:10. <u>https://doi.org/10.1186/s40168-015-0070-0</u>

PMID:<u>25825673</u>

- Ebbesen KK, Hansen TB, Kjems J. Insights into circular RNA biology. RNA Biol. 2017; 14:1035–45. <u>https://doi.org/10.1080/15476286.2016.1271524</u> PMID:<u>27982727</u>
- 22. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, Huang N, Yang X, Zhao K, Zhou H, Huang S, Xie B, Zhang N. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. 2018; 110:304–15. <u>https://doi.org/10.1093/jnci/djx166</u> PMID:<u>28903484</u>
- Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, Chen W, Gao X, Zhao K, Zhou H, Li Z, Ming L, Xie B, Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018; 37:1805–14. https://doi.org/10.1038/s41388-017-0019-9 PMID:29343848
- 24. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, Liu H, Xu J, Xiao F, Zhou H, Yang X, Huang N, Liu J, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018; 9:4475. <u>https://doi.org/10.1038/s41467-018-06862-2</u> PMID:<u>30367041</u>
- Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016; 143:1838–47. https://doi.org/10.1242/dev.128074 PMID:27246710
- 26. Wang PL, Bao Y, Yee MC, Barrett SP, Hogan GJ, Olsen MN, Dinneny JR, Brown PO, Salzman J. Circular RNA is expressed across the eukaryotic tree of life. PLoS One. 2014; 9:e90859. https://doi.org/10.1371/journal.pone.0090859 PMID:24609083
- 27. Qu S, Zhong Y, Shang R, Zhang X, Song W, Kjems J, Li H. The emerging landscape of circular RNA in life processes. RNA Biol. 2017; 14:992–99.

https://doi.org/10.1080/15476286.2016.1220473 PMID:27617908

- Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014; 20:1829–42. <u>https://doi.org/10.1261/rna.047126.114</u>
 PMID:<u>25404635</u>
- 29. Sun LF, Zhang B, Chen XJ, Wang XY, Zhang BW, Ji YY, Wu KC, Wu J, Jin ZB. Circular RNAs in human and vertebrate neural retinas. RNA Biol. 2019; 16:821–29. <u>https://doi.org/10.1080/15476286.2019.1591034</u> PMID:<u>30874468</u>
- 30. Shen L, Hu Y, Lou J, Yin S, Wang W, Wang Y, Xia Y, Wu W. CircRNA-0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR-107. Mol Med Rep. 2019; 19:3923–32. https://doi.org/10.3892/mmr.2019.10011 PMID:30864721
- 31. Hu D, Zhang Y. Circular RNA HIPK3 promotes glioma progression by binding to miR-124-3p. Gene. 2019; 690:81–89. https://doi.org/10.1016/j.gene.2018.11.073 PMID:30576808
- Devaux Y, Creemers EE, Boon RA, Werfel S, Thum T, Engelhardt S, Dimmeler S, Squire I, and Cardiolinc network. Circular RNAs in heart failure. Eur J Heart Fail. 2017; 19:701–09.

https://doi.org/10.1002/ejhf.801 PMID:28345158

- van Heesch S, Witte F, Schneider-Lunitz V, Schulz JF, Adami E, Faber AB, Kirchner M, Maatz H, Blachut S, Sandmann CL, Kanda M, Worth CL, Schafer S, et al. The Translational Landscape of the Human Heart. Cell. 2019; 178:242–260.e29. https://doi.org/10.1016/j.cell.2019.05.010 PMID:<u>31155234</u>
- Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019; 176:831–843.e22.

https://doi.org/10.1016/j.cell.2019.01.025 PMID:<u>30735634</u>

 Lei B, Huang Y, Zhou Z, Zhao Y, Thapa AJ, Li W, Cai W, Deng Y. Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression. J Cell Biochem. 2019; 120:6698–708.

https://doi.org/10.1002/jcb.27966 PMID:30506951

 Chen H, Nwe PK, Yang Y, Rosen CE, Bielecka AA, Kuchroo M, Cline GW, Kruse AC, Ring AM, Crawford JM, Palm NW. A Forward Chemical Genetic Screen Reveals Gut Microbiota Metabolites That Modulate Host Physiology. Cell. 2019; 177:1217–1231.e18. https://doi.org/10.1016/j.cell.2019.03.036 PMID:<u>31006530</u>

- Chen D, Guo Y, Qi L, Tang X, Yong T, Liu Y, Xin Y, Hu G, Ou S, Wang D, Xie Y, Burton B, Yang Wu, Q. Circular RNA NF1-419 enhances autophagy to ameliorate senile dementia by binding Dynamin-1 and Adaptor protein 2 B1 in AD-like mice. Aging (Albany NY). 2019.
- 38. Zhang X, Yan Y, Lin W, Li A, Zhang H, Lei X, Dai Z, Li X, Li H, Chen W, Chen F, Ma J, Xie Q. Circular RNA Vav3 sponges gga-miR-375 to promote epithelialmesenchymal transition. RNA Biol. 2019; 16:118–32. <u>https://doi.org/10.1080/15476286.2018.1564462</u> PMID:<u>30608205</u>
- 39. Zhou ZB, Du D, Chen KZ, Deng L, Niu YL, Zhu L. Differential expression profiles and functional predication of circRNA in traumatic spinal cord injury of rats. J Neurotrauma. 2019; 36:2287–2297. <u>https://doi.org/10.1089/neu.2018.6366</u> PMID:<u>30681027</u>
- 40. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011; 334:105–08. https://doi.org/10.1126/science.1208344 PMID:21885731
- Parashar A, Udayabanu M. Gut microbiota: implications in Parkinson's disease. Parkinsonism Relat Disord. 2017; 38:1–7. <u>https://doi.org/10.1016/j.parkreldis.2017.02.002</u> PMID:<u>28202372</u>
- 42. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016; 167:1469–1480.e12. <u>https://doi.org/10.1016/j.cell.2016.11.018</u> PMID:<u>27912057</u>
- 43. Zhang J, Song L, Wang Y, Liu C, Zhang L, Zhu S, Liu S, Duan L. Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats. J Gastroenterol Hepatol. 2019; 8:1368–1376. https://doi.org/10.1111/jgh.14536 PMID:30402954
- 44. Gan XN, Gan TQ, He RQ, Luo J, Tang RX, Wang HL, Zhou H, Qing H, Ma J, Hu XH, Chen G. Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma. Oncol Lett. 2018; 15:6418–30. https://doi.org/10.3892/ol.2018.8088 PMID:29616113
- 45. Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong W, Gong D,

Zheng J, Xue W, Xu Y. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals. Mol Cancer. 2018; 17:157.

https://doi.org/10.1186/s12943-018-0906-x PMID:<u>30419914</u>

- 46. Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, et al. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017; 31:853–60. <u>https://doi.org/10.1038/leu.2016.296</u> PMID:27773931
- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38:e164. <u>https://doi.org/10.1093/nar/gkq603</u> PMID:<u>20601685</u>
- Xin W, Liu X, Ding J, Zhao J, Zhou Y, Wu Q, Hua K. Long non-coding RNA derived miR-205-5p modulates human endometrial cancer by targeting PTEN. Am J Transl Res. 2015; 7:2433–41. PMID:<u>26807189</u>
- 49. Tao W, Sun W, Zhu H, Zhang J. miR-205-5p suppresses pulmonary vascular smooth muscle cell proliferation by targeting MICAL2-mediated Erk1/2 signaling. Microvasc Res. 2019; 124:43–50. <u>https://doi.org/10.1016/j.mvr.2019.03.001</u>
 PMID:30853343
- Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28:511–15.

https://doi.org/10.1038/nbt.1621 PMID:20436464

- 51. Roberts A, Pimentel H, Trapnell C, Pachter L. Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics. 2011; 27:2325–29. https://doi.org/10.1093/bioinformatics/btr355 PMID:21697122
- 52. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9:357–59. https://doi.org/10.1038/nmeth.1923 PMID:22388286
- 53. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. <u>https://doi.org/10.1186/1471-2105-12-323</u> PMID:<u>21816040</u>
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26:139–40. <u>https://doi.org/10.1093/bioinformatics/btp616</u>

PMID:19910308

 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29:15–21. https://doi.org/10.1093/bioinformatics/bts635

PMID:23104886

- 56. Cheng J, Metge F, Dieterich C. Specific identification and quantification of circular RNAs from sequencing data. Bioinformatics. 2016; 32:1094–96. <u>https://doi.org/10.1093/bioinformatics/btv656</u> PMID:26556385
- 57. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol.

2003; 5:R1. https://doi.org/10.1186/gb-2003-5-1-r1 PMID:<u>14709173</u>

- 58. Chen I, Chen CY, Chuang TJ. Biogenesis, identification, and function of exonic circular RNAs. Wiley Interdiscip Rev RNA. 2015; 6:563–79. <u>https://doi.org/10.1002/wrna.1294</u> PMID:26230526
- 59. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017; 8:253–67.

https://doi.org/10.1080/19490976.2017.1293224 PMID:<u>28609252</u>

SUPPLEMENTARY MATERIALS

Supplementary Figures



Supplementary Figure 1A. Heatmap of gut microbiota in 10-month-old AD-like mice. Data are presented as the means of more than 8 independent experiments.



Supplementary Figure 1B. Heatmap of gut microbiota in 10-month-old AD-like mice. Data are presented as the means of more than 8 independent experiments.

| 7-Ketodeoxycholic acid - | | | | | | | | | | | | | | | | | | | | | |
|--|-------|------|------|-------|-------|------|--------------|-------|--------------|--------------|--------|-----|-------|------|-----|----|-------------|------|----------|--------------|------------------------------------|
| 7a,12a-Dihydroxy-3-oxo-4-cholenoic acid - | • | • | + | • | + | + | -+- | - ÷ - | ÷ - | - ÷ | ÷ | + | • | • • | • | • | | • | ÷ ÷ | - /• | |
| 3b,7a,12a-Trihydroxy-5b-cholanoic acid PC(18:1(9Z)/18:2(9Z,12Z)) - | | 1 | | 1 | | 1 | 1 | | 1 | - 1 | 100 | 1 | : | | | | | : | : : | | |
| PC(18:0/18:1(9Z)) - | • | • | | • | • | • | • | • | - ÷- | • | • | | | | | | • | • | · · · | | |
| LysoPE(22:0/0:0) - Cholesterol - | | - 1 | 1 | 1 | 1 | 1 | 1 | 1 | - 1 - | - 11 | | 1 | : | | : | 1 | 1 | : | : /: | - 41 | |
| Nonadecanoic acid - | • | - 1 | - 1 | | - 1- | - ÷- | 1.1 | | - 1- | - 1 | - A. | - C | | | | | | 1 | | | |
| LysoPC(20:0) - | • | • | • | • | - ÷ - | · • | • | • | · • | - ÷- | • | + | • | • • | • | • | • | • | • • | | |
| Pentadecanoic acid - LysoPC(22:4(7Z,10Z,13Z,16Z)) - | | - : | 1 | | - : | | | - 1- | - 1- | - 11 | - 1 | 1 | : | | | | | | : : | | |
| PGP(18:1(9Z)/18:0) - | | • | • | • | • | • | • | • | • | • | • | • | • • | • • | • | • | • | • | • • | - • | |
| Gamma Hydroxybutyric Acid - LysoPC(20:5(5Z,8Z,11Z,14Z,17Z)) - | | | | | | | | | - 1 | | | | : | | | | | : | : : | | |
| 11-beta-Hydroxyandrosterone-3-glucuronide - | • | • | • | • | + | • | • | • | • | | | | • | • • | • | • | • | • | • • | • | |
| L-Acetylcarnitine - LysoPE(20:5(5Z,8Z,11Z,14Z,17Z)/0:0) - | • | | | | | | | | | | | | | | | | 2 | ? | | | |
| Stearidonic acid - | • | | | | | | | | | | | | | | | | · | - | | | |
| Linoelaidic acid - | | • | | • | | | | | | . • | | | • | • • | • | • | • | • | • • | • | |
| 9,13-cis-Retinoate - Eicosapentaenoic acid - | | | | | | | | | | | | ÷ | | | | | | | | - 6 | |
| 2-Methylbutyroylcarnitine - | • | • | | • | | | • | - ÷- | | • | - ÷ - | ÷ | • | • • | | | - | • | | | |
| PI(18:2(9Z,12Z)/16:0) - Erucic acid - | • | • | | • | • | | • | | • | • | | | • | • | • | | | • | | • | |
| 3,7R,11R,15-tetramethyl-hexadecanoic acid - | • | | | • | - Q., | | | ÷. | ÷. | | - ÷ - | 4 | | | | | | | · /• | | |
| Linolenelaidic acid - | • | • | • | • | • | • | • | • | • | • | • | • | • | | | • | • | • | • | • | |
| PC(16:0/18:2(9Z,12Z)) - LysoPE(18:0/0:0) - | : | - 1 | | | | | | | | - 1 | 100 | | : | | | | | : | | - 1 - | |
| 10-Methyltridecanoic acid - | • | | | | | | | | | | | | • | • • | | • | | • | | | |
| PI(20:3(5Z,8Z,11Z)/18:2(9Z,12Z)) - Tetranor 12-HETE - | • | • | • | | | | | | | | | | | | | | | | | | |
| LysoPC(18:1(11Z)) - | • | | | | | | | | | | | | | | | | | | | | |
| PC(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)) - | • | • | • | • | | | | | | | | | • | • • | | • | • | • | • • | • | |
| LysoPC(18:3(9Z,12Z,15Z)) - PE(20:4(8Z,11Z,14Z,17Z)/24:1(15Z)) - | | 1 | | | | | 100 | | | | | | | | | | | | | | value |
| PI(18:3(9Z,12Z,15Z)/18:0) - | | • | • | • | • | | | | | | | • | | | i | | • | • | | | |
| Citric acid - Eicosenoic acid - | • | 1 | | : | : | 1 | 1 | 1 | 1 | : | 1 | : / | : / | : | • | : | : | : | : | : | • 0 |
| Eicosenoic acid PI(18:3(9Z,12Z,15Z)/18:1(9Z) | ė | • | | | | | | | | | | 6 | | | - 0 | Ö | ò | i i | i i | Ö | • 100 |
| PE(P-18:1(9Z)/20:3(8Z,11Z,14Z)) - | • | • | • | - Ŧ- | - Ŧ- | - ÷- | - ÷- | - Ŧ- | -Ŧ- | - ÷- | - Ŧ- | Ŧ - | Ŧ - 1 | | • | | • | • | · · | • | • 200 |
| (5E,7E,11E,14E,17E)-9-hydroxyicosa-5,7,11,14,17-pentaenoic acid - PE(22:5(7Z,10Z,13Z,16Z,19Z)/20:3(8Z,11Z,14Z)) - | | - : | | | | | | | - 1 | - 1 | | | : | | | | | | : : | | 300 |
| LvsoPE(20:0/0:0) - | • | | | | | | | | | | | - | | | | | | | | | 0.000 |
| PC(18:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) - | • | • | • | • | • | • | • | • | | • | | | • | • • | • | • | • | | • • | | |
| LysoPC(18:4(6Z,9Z,12Z,15Z)) - L-Malic acid - | | - 1 | | | - : | | | | 1 | - 17 | | - | | | | | | | : : | | variable |
| LysoPC(20:3(8Z,11Z,14Z)) - | | • | • | • | | • | | • | • | - • | | | • | • • | • | • | • | • | • • | • | • M1 • N1 |
| 4,8,12,15,19-Docosapentaenoic acid 11,14,17-Eicosatrienoic acid | | - : | 1 | | 1 | 1 | | 1 | - 1 | 1: | | 1 | : | | | | 1 | : | : : | - 1 | • M2 • N2 |
| PC(14:1(9Z)/18:1(9Z)) - | | | | | | | - - - | | - I . | | | | | | | | | | | | • M3 • N3 |
| Dihomo-linoleate (20:2n6) - | | • | • | • | | • | • | • | • | | • | • | • | • • | • | • | • | • | • • | • | |
| Benzoyl glucuronide (Benzoic acid) - PE(22:5(7Z,10Z,13Z,16Z,19Z)/P-16:0) - | | | | | | | | | - 11 | | | 1 | : | | | | | : | : : | | • M4 • N4 |
| PI(16:0/22:2(13Z,16Z)) - | | • | • | • | • | • | • | • | - • - | | | | • | • • | • | • | • | | • • | • | • M5 • N5 |
| PC(22:5(7Z,10Z,13Z,16Z,19Z)/16:0) - MG(22:5(4Z,7Z,10Z,13Z,16Z)/0:0/0:0) - | • | • | | | | | | • | • | | | | • | | • | • | | • | • | | M6 N6 |
| PC(18:4(6Z,9Z,12Z,15Z)/20:0) - | | | | | | | | | | | | | | | | | | | | | • M7 • N7 |
| PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0) - | • | | | • | • | • | • | • | • | - * | | | • | • • | • | • | • | • | • • | • | • M8 • N8 |
| PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)) - PC(20:3(5Z,8Z,11Z)/P-18:1(11Z)) - | | | | | | | | | - 1 | | | | : | | | | : | : | : : | | • M9 • N9 |
| 12 Hydroxy arachidonic acid - | • | • | | | | | | | • | | - | • | • | 0 | | • | • | • | | • | |
| L-Valine - PE(22:1(13Z)/22:5(7Z,10Z,13Z,16Z,19Z)) - | | | | - | | - | - | - | - | - | - | - | : | | | - | - | : | : : | | • M10 • N10 |
| PE(P-16:0e/0:0) - | • | | | | | | | | | | | | | | | | | | | | • M11 • N11 |
| PC(P-18:1(9Z)/18:1(9Z)) - | | • | • | • | | | | • | | • | • | • | • | • • | | • | • | • | • • | • | |
| Sphingosine 1-phosphate - PG(18:0/20:3(8Z,11Z,14Z)) - | | - 1 | | | - 1 | 1 | | | | | | 1 | 1 | | | 1 | | 1 | | | |
| LysoPC(22:5(7Z,10Z,13Z,16Z,19Z)) - | • | | • | • | + | • | • | • | | | | | | • • | • | • | | • | • • | • | |
| PC(20:4(5Z,8Z,11Z,14Z)/P-18:1(9Z)) - PG(18:1(9Z)/20:3(8Z,11Z,14Z)) - | 1 | | 1 | 1 | 1 | 1 | 1 | | 1. | 11 | | 1 | : | | 1 | 1 | 1 | 1 | 1 1 | - 1 | |
| Isopimaric acid - | | - | | | | | | | | | | | | | | | | | | | |
| 5,6-Dihydroxyprostaglandin F1a | • | | | | | • | | • | 1 | - * - | | | • | • • | • | • | • | • | • • | • | |
| PI(22:3(10Z,13Z,16Z)/16:0) - PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)) - | | | | | | | | | | | | 1 | | | | | | | | | |
| PC(18:2(9Z,12Z)/P-16:0) - | | | | | | + | | | | + | | | | | | | | : | <u>.</u> | : | |
| PE(22:1(13Z)/P-18:1(11Z)) - PE(22:5(7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z)) - | | -• | | | | | | | | | | | • | | • | | | • | | | |
| PC(18:3(6Z,9Z,12Z)/18:0) - | | | | | | | | • | | | | | | | | • | | | | | |
| PC(18:3(6Z,9Z,12Z)/P-18:1(11Z)) - | • | • | | • | | | | | | | | 1 | : | • | • | | | : | : • | • | |
| Diethylphosphate - 15(S)-Hydroxyeicosatrienoic acid - | | | | | | | 1 | | | | | | | | | | | : | : : | | |
| PC(20:2(11Z,14Z)/20:3(5Z,8Z,11Z)) - | · • | • | • | | | | | | • | | | | • | | • | | | • | • • | • | |
| PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)) - PE(P-18:1(9Z)/20:3(5Z.8Z.11Z)) - | | : | 1 | : | : | : | : | 1 | 1 | | 1.1 | 1 | : | | : | : | : | 1 | 1 1 | | |
| PC(20:3(5Z.8Z.11Z)/20:3(8Z.11Z.14Z)) - | | ė | Ö | | | • | | | • | | Ó | | • | | Ó | Ó | | • | • | | |
| PE(22:0/P-18:1(9Z)) - | • | 1 | - | | - | • | | - | - | - | - | 1 | : | | • | : | : | : | : : | • | |
| PC(20:0/18:3(6Z,9Z,12Z)) - PE(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)) - | | • | | | | | | | | | | | | | | | | | | | |
| PC(22:5(7Z,10Z,13Z,16Z,19Z)/18:0) - | | • | | • | • | • | • | • | | | • | • | • | • • | • | • | • | • | • • | • | |
| 2-Hydroxy-6-pentadecylbenzoic acid - MG(22:5(7Z,10Z,13Z,16Z,19Z)/0:0/0:0) - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 1 | 1 | 1 | 1 | : : | 1 | |
| Hippuric acid - | • | | | | | | | | - 1 | | | 1. | | | | | | | 1 1 | | |
| Palmitovi glucuronide - | | • | | • | | | | | | | | 1 | : | • • | • | | | • | • • | | |
| PC(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) - Stearoyllactic acid - | | | | | | | | | | 1 | | 1. | : | | - 1 | : | 1 | : | 1 1 | | |
| DG(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0) - | • | | | | | | | | | | | | • | • • | | | | | • | | |
| PC(20:3(5Z,8Z,11Z)/14:0) - Phenol sulphate - | 1 | 1 | 1 | 1 | 1 | - | | 1 | 1 | 1 | 1 | 1 | 1 | | 1 | 1 | 1 | : | 1 | : | |
| Friendl sulphate - | M1 | M2 | МЗ | M4 | M5 | MG | MZ | MB | мэ | M10 | M11 | N1 | N2 N | 3 N4 | N5 | NG | NZ | N8 I | 19 N10 | N11 | |
| | ALL I | WIZ. | 1410 | 14144 | 110 | 110 | | 1410 | 110 | | varial | | · · • | | .40 | | <u>an</u> . | | | | |
| | | | | | | | | | | | | | | | | | | | | | |

Supplementary Figure 2A. Heatmap of serum metabolites in 10-month-old AD-like mice. Data are presented as the means of more than 8 independent experiments.



Supplementary Figure 2B. Heatmap of serum metabolites in in 10-month-old AD-like mice. Data are presented as the means of more than 8 independent experiments.



Supplementary Figure 3. The networks of Ingenuity Canonical Pathways (IPA) analysis of differentially expressed mRNAs in the APP/PS1 double transgenic mice brain samples (n=3)



Supplementary Figure 4. AAV viral transduction system with RNA interference (sicircNF1-419-AAV, A–B) and separately an over-expressing circNF1-419 (sscircNF1-419-AAV, C–D)



Supplementary Figure 5. Differential expression mRNAs of the small intestine tissue on the *circNF1-419* treated SAMP8 (A) and KM mice (B). Data are presented as the means of 3 independent experiments.





Supplementary Figure 6. AAV viral transduction system with RNA over-expressing mmu_circ_0001239

Supplementary Table

Please browse Full Text version to see the data of Supplementary Table 1. Different expression of circRNAs in the brain of APP/PS1 mice (control vs model group, Foldchange > 1.50, p < 0.01).